JP2012518624A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012518624A5 JP2012518624A5 JP2011550652A JP2011550652A JP2012518624A5 JP 2012518624 A5 JP2012518624 A5 JP 2012518624A5 JP 2011550652 A JP2011550652 A JP 2011550652A JP 2011550652 A JP2011550652 A JP 2011550652A JP 2012518624 A5 JP2012518624 A5 JP 2012518624A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- toxin
- difficile
- composition according
- sheep
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108090001123 antibodies Proteins 0.000 claims 25
- 102000004965 antibodies Human genes 0.000 claims 25
- 231100000765 Toxin Toxicity 0.000 claims 15
- 239000003053 toxin Substances 0.000 claims 15
- 108020003112 toxins Proteins 0.000 claims 15
- 239000000203 mixture Substances 0.000 claims 13
- 101700023105 3L21 Proteins 0.000 claims 8
- 241000283898 Ovis Species 0.000 claims 8
- 101710037563 alpha-delta-Bgt-2 Proteins 0.000 claims 8
- 101700085332 3L23 Proteins 0.000 claims 4
- 101700012833 3S11 Proteins 0.000 claims 4
- 101700057439 TOXA Proteins 0.000 claims 4
- 101700041767 ctxA Proteins 0.000 claims 4
- 239000008194 pharmaceutical composition Substances 0.000 claims 4
- 101700080113 toxB Proteins 0.000 claims 4
- 201000009910 diseases by infectious agent Diseases 0.000 claims 3
- 230000002163 immunogen Effects 0.000 claims 3
- 238000004519 manufacturing process Methods 0.000 claims 3
- 241000193163 Clostridioides difficile Species 0.000 claims 2
- 230000002265 prevention Effects 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 1
- 238000007911 parenteral administration Methods 0.000 claims 1
- 239000000546 pharmaceutic aid Substances 0.000 claims 1
- 108091008117 polyclonal antibodies Proteins 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 239000011780 sodium chloride Substances 0.000 claims 1
Claims (13)
- Ｃ．ディフィシル（C. difficile）感染の予防または処置において使用するためのヒツジ抗体を含む抗体組成物であって、前記抗体はＣ．ディフィシル毒素に結合する、前記抗体組成物。
- 抗体がポリクローナル抗体である、請求項１記載の抗体組成物。
- 抗体が、Ｃ．ディフィシル毒素Ａ、Ｃ．ディフィシル毒素ＢおよびＣ．ディフィシル二元毒素からなる群より選択される少なくとも１つのＣ．ディフィシル毒素に結合する、請求項１〜２のいずれか記載の抗体組成物。
- 抗体がＣ．ディフィシル毒素ＡおよびＣ．ディフィシル毒素Ｂに結合する、請求項３記載の抗体組成物。
- 抗体がＣ．ディフィシル毒素ＡおよびＣ．ディフィシル二元毒素に結合する、請求項３記載の抗体組成物。
- 抗体がＣ．ディフィシル毒素ＢおよびＣ．ディフィシル二元毒素に結合する、請求項３記載の抗体組成物。
- Ｃ．ディフィシル毒素が、以下の群：毒素タイプ０、毒素タイプＩＩＩおよび毒素タイプＶから選択される毒素Ａである、請求項１〜５のいずれか記載の抗体組成物。
- Ｃ．ディフィシル毒素が、以下の群：毒素タイプ０、毒素タイプＩＩＩおよび毒素タイプＶから選択される毒素Ｂである、請求項１〜３、請求項４または請求項６のいずれか記載の抗体組成物。
- 請求項１〜８記載の抗体組成物を、薬学的に許容される担体、賦形剤および／または塩から選択された少なくとも１つの成分と一緒に含む、非経口投与のための、薬学的組成物。
- Ｃ．ディフィシル感染の予防または処置のための方法であって、前記方法は、請求項１〜８記載の抗体組成物または請求項９記載の薬学的組成物を投与することを含む、前記方法。
- 請求項１〜８記載の抗体組成物において使用するための、または請求項９記載の薬学的組成物において使用するための、ヒツジ抗体を生産する方法であって、前記ヒツジ抗体は、Ｃ．ディフィシル毒素またはそのフラグメントを含む免疫原に応答してヒツジによって誘発される、前記方法。
- 請求項１〜７記載の抗体組成物において使用するための、または請求項８記載の薬学的組成物において使用するためのヒツジ抗体を生産する方法であって、前記方法は、（ｉ）Ｃ．ディフィシル毒素またはそのフラグメントを含む免疫原をヒツジに投与する工程、（ｉｉ）ヒツジにおける抗体の生成のために十分な時間をかける工程、そして（ｉｉｉ）ヒツジから抗体を得る工程を含む、前記方法。
- 免疫原がＣ．ディフィシルトキソイドである、請求項１１または請求項１２記載の方法。
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0902851.5 | 2009-02-20 | ||
| GB0902851A GB0902851D0 (en) | 2009-02-20 | 2009-02-20 | Antibodies to clostridium difficile toxins |
| GB0916153A GB0916153D0 (en) | 2009-09-15 | 2009-09-15 | Antibodies to clostridium difficile toxins |
| GB0916153.0 | 2009-09-15 | ||
| PCT/GB2010/050288 WO2010094970A1 (en) | 2009-02-20 | 2010-02-19 | Antibodies to clostridium difficile toxins |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2012518624A JP2012518624A (ja) | 2012-08-16 |
| JP2012518624A5 true JP2012518624A5 (ja) | 2013-03-07 |
| JP5740714B2 JP5740714B2 (ja) | 2015-06-24 |
Family
ID=42109880
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011550652A Active JP5740714B2 (ja) | 2009-02-20 | 2010-02-19 | クロストリジウム・ディフィシル（Ｃｌｏｓｔｒｉｄｉｕｍｄｉｆｆｉｃｉｌｅ）毒素に対する抗体 |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US8709428B2 (ja) |
| EP (1) | EP2405940B1 (ja) |
| JP (1) | JP5740714B2 (ja) |
| CN (1) | CN102365097A (ja) |
| AU (1) | AU2010215275B2 (ja) |
| CA (1) | CA2752815A1 (ja) |
| WO (1) | WO2010094970A1 (ja) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0921288D0 (en) | 2009-12-04 | 2010-01-20 | Health Prot Agency | Therapies for preventing or suppressing clostridium difficile infection |
| US8431361B2 (en) | 2010-09-17 | 2013-04-30 | Board Of Regents Of The University Of Oklahoma | Bacterial cells, optimized nucleotide sequences and methods for improved expression of recombinant Clostridium difficile toxin B |
| JP5917682B2 (ja) | 2011-04-22 | 2016-05-18 | ワイス・エルエルシー | 変異体クロストリジウム・ディフィシル毒素に関する組成物およびその方法 |
| GB201110712D0 (en) | 2011-06-23 | 2011-08-10 | Univ Ulster | Diagnostic methods |
| KR20140063825A (ko) * | 2011-09-16 | 2014-05-27 | 유씨비 파마, 에스.에이. | 클로스트리듐 디피실의 주요 외독소 tcda 및 tcdb에 대한 중화 항체 |
| WO2013071409A1 (en) | 2011-11-18 | 2013-05-23 | National Research Council Of Canada (Nrc) | Clostridium difficile lipoteichoic acid and uses thereof |
| US9694063B2 (en) | 2011-12-08 | 2017-07-04 | Glaxosmithkline Biologicals Sa | Clostridium difficile toxin-based vaccine |
| DE102011121237A1 (de) * | 2011-12-14 | 2013-06-20 | Universitätsklinikum Hamburg-Eppendorf | Einzeldomänen-Antikörper gegen Clostridium difficile Toxin CDTa |
| AR089797A1 (es) * | 2012-01-27 | 2014-09-17 | Merck Sharp & Dohme | Vacunas contra clostridum difficile que comprenden toxinas recombinantes |
| WO2013130981A1 (en) | 2012-03-02 | 2013-09-06 | Regeneron Pharmaceuticals, Inc. | Human antibodies to clostridium difficile toxins |
| WO2014061783A1 (ja) | 2012-10-19 | 2014-04-24 | 株式会社イーベック | クロストリジウム・ディフィシルの毒素に特異的なヒト抗体もしくはその抗原結合性断片 |
| BR122016023101B1 (pt) | 2012-10-21 | 2022-03-22 | Pfizer Inc | Polipeptídeo, composição imunogênica que o compreende, bem como célula recombinante derivada de clostridium difficile |
| CA2892973A1 (en) * | 2012-11-28 | 2014-06-05 | Cnj Holdings, Inc. | Antibodies against clostridium difficile |
| US9493518B2 (en) * | 2013-03-14 | 2016-11-15 | National Health Research Institutes | Compositions and methods for treating clostridium difficile-associated diseases |
| ES2940827T3 (es) * | 2013-04-19 | 2023-05-11 | Immuron Ltd | Procedimientos y composiciones para el tratamiento y/o la profilaxis de la enfermedad asociada a Clostridium difficile |
| CN105451762A (zh) * | 2013-04-22 | 2016-03-30 | 俄克拉荷马州大学评议会 | 艰难梭菌疫苗及使用方法 |
| CN103665141B (zh) * | 2013-12-31 | 2015-09-16 | 北京大学 | 与艰难梭菌细胞毒素b相互作用的蛋白 |
| WO2015150493A1 (en) * | 2014-04-01 | 2015-10-08 | Institut Pasteur | Predictive value of clostridium difficile-specific immune response for recurrence and disease outcome |
| US10709758B2 (en) | 2015-09-03 | 2020-07-14 | The Board Of Regents Of The University Of Oklahoma | Peptide inhibitors of clostridium difficile toxin B (TcdB) toxin |
| USD952157S1 (en) | 2020-06-19 | 2022-05-17 | Qualigen Inc. | Whole blood treatment cartridge |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS608225A (ja) | 1983-06-29 | 1985-01-17 | Kowa Co | 腸管吸収医薬組成物 |
| US5601823A (en) | 1989-10-31 | 1997-02-11 | Ophidian Pharmaceuticals, Inc. | Avian antitoxins to clostridium difficle toxin A |
| NZ291659A (en) | 1994-09-06 | 2001-04-27 | Galagen Inc | Use in the manufacture of a medicament of an antibody having specific activity against Clostridium difficile, and pharmaceutical compositions comprising Anti-Clostridium difficile bovine immunoglobulin concentrate; for treating diseases associated with Clostridium difficile |
| US6096310A (en) | 1997-04-15 | 2000-08-01 | Bier; Milan | Oral immunotherapy of bacterial overgrowth |
| WO1998059053A1 (en) | 1997-06-20 | 1998-12-30 | Queen Mary & Westfield College | Immonogenic fragments of toxin a of clostridium difficile |
| US6969520B2 (en) | 1997-10-20 | 2005-11-29 | Acambis Inc. | Active immunization against clostridium difficile disease |
| EP1024826B1 (en) * | 1997-10-20 | 2005-03-16 | Acambis, Inc. | Passive immunization against clostridium difficile disease |
| US6074689A (en) | 1998-03-10 | 2000-06-13 | Immucell Corporation | Colonic delivery of protein or peptide compositions |
| US20020009429A1 (en) * | 1999-01-29 | 2002-01-24 | Galagen, Inc. | Pharmaceutical composition comprising a selected antigen and candida species antigen and methods |
| US6673574B2 (en) | 2000-11-30 | 2004-01-06 | Unigene Laboratories Inc. | Oral delivery of peptides using enzyme-cleavable membrane translocators |
| GB0205206D0 (en) | 2002-03-06 | 2002-04-17 | Oxoid Ltd | Synthetic peptides |
| AU2003299527A1 (en) | 2002-06-17 | 2004-06-07 | Jimmy D. Ballard | Mutant of clostridium difficile toxin b and methods of use |
| GB0309126D0 (en) | 2003-04-17 | 2003-05-28 | Neutec Pharma Plc | Clostridium difficile focussed antibodies |
| PT2270045E (pt) * | 2004-02-06 | 2015-04-08 | Univ Massachusetts | Anticorpos contra toxinas de clostridium difficile e utilizações dos mesmos |
| CA2592015A1 (en) * | 2004-12-27 | 2006-07-06 | Progenics Pharmaceuticals (Nevada), Inc. | Orally deliverable and anti-toxin antibodies and methods for making and using them |
| US7794721B2 (en) | 2006-12-13 | 2010-09-14 | Simon Michael R | Synthesis of human secretory IgM and the treatment of clostridium difficile associated diseases herewith |
| CN101363867B (zh) * | 2008-05-26 | 2012-12-19 | 北京庄笛浩禾生物医学科技有限公司 | 一种艰难梭菌a、b毒素胶体金检测试纸条及其制备方法 |
| GB0921288D0 (en) | 2009-12-04 | 2010-01-20 | Health Prot Agency | Therapies for preventing or suppressing clostridium difficile infection |
-
2010
- 2010-02-19 AU AU2010215275A patent/AU2010215275B2/en active Active
- 2010-02-19 EP EP10706731.6A patent/EP2405940B1/en active Active
- 2010-02-19 WO PCT/GB2010/050288 patent/WO2010094970A1/en active Application Filing
- 2010-02-19 CA CA2752815A patent/CA2752815A1/en not_active Abandoned
- 2010-02-19 CN CN2010800086731A patent/CN102365097A/zh active Pending
- 2010-02-19 JP JP2011550652A patent/JP5740714B2/ja active Active
- 2010-02-19 US US13/202,557 patent/US8709428B2/en active Active
-
2014
- 2014-03-18 US US14/218,854 patent/US20150010580A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2012518624A5 (ja) | ||
| JP2015078220A5 (ja) | ||
| JP2014169326A5 (ja) | ||
| JP2012121878A5 (ja) | ||
| JP2012193216A5 (ja) | ||
| JP2017503820A5 (ja) | ||
| JP2018505882A5 (ja) | ||
| EA201270221A1 (ru) | Лечение болезни крона с применением лаквинимода | |
| JP2015517488A5 (ja) | ||
| JP2016040284A5 (ja) | ||
| JP2010285439A5 (ja) | ||
| JP2016503413A5 (ja) | ||
| JP2015522252A5 (ja) | ||
| JP2016502515A5 (ja) | ||
| UA111599C2 (uk) | Композиція каспофунгіну | |
| JP2016539125A5 (ja) | ||
| JP2015524816A5 (ja) | ||
| JP2015530399A5 (ja) | ||
| RU2015134422A (ru) | Применение левоцитиризина и монтелукаста при лечении васкулита | |
| RU2018125622A (ru) | Способ применения карримицина против резистетности инфекции, спровоцированной микобактерией туберкулеза | |
| EA201000039A1 (ru) | Фармацевтическая композиция, включающая солифенацин или его фармацевтически приемлемую соль | |
| JP2013523758A5 (ja) | ||
| JP2016531853A5 (ja) | ||
| JP2017519762A5 (ja) | ||
| JP2008539169A5 (ja) |